Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis.
Biomarkers
Diffusion magnetic resonance imaging
Meta-analysis
Multiple myeloma
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
29
03
2021
accepted:
30
08
2021
revised:
27
07
2021
pubmed:
15
1
2022
medline:
17
3
2022
entrez:
14
1
2022
Statut:
ppublish
Résumé
Myeloma Response Assessment and Diagnosis System recently published provides a framework for the standardised interpretation of DW-WBMRI in response assessment of multiple myeloma (MM) based on expert opinion. However, there is a lack of meta-analysis providing higher-level evidence to support the recommendations. In addition, some disagreement exists in the literature regarding the effect of timing and lesion subtypes on apparent diffusion coefficient (ADC) value changes post-treatment. Medline, Cochrane and Embase were searched from inception to 20th July 2021, using terms reflecting multiple myeloma and DW-WBMRI. Using PRISMA reporting guidelines, data were extracted by two investigators. Quality was assessed by the Quality Assessment of Diagnostic Accuracy Studies-2 method. Of the 74 papers screened, 10 studies were included comprising 259 patients (127 males and 102 females) and 1744 reported lesions. Responders showed a significant absolute ADC change of 0.21×10 This meta-analysis supports the use of the DW-WBMRI as an imaging biomarker for response assessment. More evidence is needed to further characterise ADC changes by lesion subtypes over time. • In multiple myeloma patients who received chemotherapy, responders have a significant absolute increase in ADC values that is not seen in non-responders. • A 35% increase in ADC from baseline values is found to classify response post-induction chemotherapy which corroborates with expert opinion from the Myeloma Response Assessment and Diagnosis System. • More evidence is needed to further characterise ADC changes by lesion subtypes over time after induction of therapy.
Identifiants
pubmed: 35028748
doi: 10.1007/s00330-021-08311-z
pii: 10.1007/s00330-021-08311-z
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2135-2148Informations de copyright
© 2021. Crown.
Références
Barwick T, Bretsztajn L, Wallitt K et al (2019) Imaging in myeloma with focus on advanced imaging techniques. Br J Radiol 92:20180768
doi: 10.1259/bjr.20180768
pubmed: 30604631
pmcid: 6540859
Cancer Research UK (2017) Myeloma incidence statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/incidence . Accessed 20 Aug 2020
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https://doi.org/10.3322/caac.21660.Epu
Harry VN, Semple SI, Parkin DE, Gilbert FJ (2010) Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 11:92–102
doi: 10.1016/S1470-2045(09)70190-1
pubmed: 20129132
Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328–e346
doi: 10.1016/S1470-2045(16)30206-6
pubmed: 27511158
Chantry A, Kazmi M, Barrington S et al (2017) Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol 178:380–393. https://doi.org/10.1111/bjh.14827
doi: 10.1111/bjh.14827
pubmed: 28677897
The National Institute for Health and Care Excellence (NICE) (2018) Myeloma: diagnosis and management (NG35). https://www.nice.org.uk/guidance/ng35 . Accessed 10 Aug 2020
Messiou C, Hillengass J, Delorme S et al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology 291:5–13. https://doi.org/10.1148/radiol.2019181949
doi: 10.1148/radiol.2019181949
pubmed: 30806604
Yao K, Troupis JM (2016) Diffusion-weighted imaging and the skeletal system: a literature review. Clin Radiol 71:1071–1082
doi: 10.1016/j.crad.2016.07.007
pubmed: 27519973
Hillengass J, Bäuerle T, Bartl R et al (2011) Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol 153:721–728. https://doi.org/10.1111/j.1365-2141.2011.08658.x
doi: 10.1111/j.1365-2141.2011.08658.x
pubmed: 21517815
Dutoit JC, Verstraete KL (2016) MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings. Insights Imaging 7:553–569
doi: 10.1007/s13244-016-0492-7
pubmed: 27164915
pmcid: 4956620
Fenchel M, Konaktchieva M, Weisel K et al (2010) Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging. A feasibility study. Acad Radiol 17:1326–1333. https://doi.org/10.1016/j.acra.2010.08.002
doi: 10.1016/j.acra.2010.08.002
pubmed: 20817572
Horger M, Weisel K, Horger W et al (2011) Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol 196:W790–W795. https://doi.org/10.2214/AJR.10.5979
Messiou C, Giles S, Collins DJ et al (2012) Assessing response of myeloma bone disease with diffusion-weighted MRI. Br J Radiol 85:e1198–e1203. https://doi.org/10.1259/bjr/52759767
doi: 10.1259/bjr/52759767
pubmed: 23175485
pmcid: 3611724
Giles SL, Messiou C, Collins DJ et al (2014) Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology 271:785–794. https://doi.org/10.1148/radiol.13131529
doi: 10.1148/radiol.13131529
pubmed: 24475858
Bonaffini PA, Ippolito D, Casiraghi A et al (2015) Apparent diffusion coefficient maps integrated in whole-body MRI examination for the evaluation of tumor response to chemotherapy in patients with multiple myeloma. Acad Radiol 22:1163–1171. https://doi.org/10.1016/j.acra.2015.05.011
doi: 10.1016/j.acra.2015.05.011
pubmed: 26182979
Dutoit JC, Claus E, Offner F, Noens L, Delanghe J, Verstraete KL (2016) Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma. Eur J Radiol 85:373–382. https://doi.org/10.1016/j.ejrad.2015.11.040
Latifoltojar A, Hall-Craggs M, Bainbridge A et al (2017) Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. Eur Radiol 27:5325–5336. https://doi.org/10.1007/s00330-017-4907-8
doi: 10.1007/s00330-017-4907-8
pubmed: 28656463
pmcid: 5674123
Lacognata C, Crimì F, Guolo A et al (2017) Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma. Clin Radiol 72:850–857. https://doi.org/10.1016/j.crad.2017.05.004
doi: 10.1016/j.crad.2017.05.004
pubmed: 28587715
Wu C, Huang J, Bin XW et al (2018) Discriminating depth of response to therapy in multiple myeloma using whole-body diffusion-weighted MRI with apparent diffusion coefficient: preliminary results from a single-center study. Acad Radiol 25:904–914. https://doi.org/10.1016/j.acra.2017.12.008
doi: 10.1016/j.acra.2017.12.008
pubmed: 29373210
Zhang Y, Xiong X, Fu Z et al (2019) Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: a large single-center cohort study. Eur J Radiol 120:108695. https://doi.org/10.1016/j.ejrad.2019.108695
doi: 10.1016/j.ejrad.2019.108695
pubmed: 31589995
Takasu M, Kondo S, Akiyama Y et al (2020) Assessment of early treatment response on MRI in multiple myeloma: comparative study of whole-body diffusion-weighted and lumbar spinal MRI. PLoS One 15:e0229607. https://doi.org/10.1371/journal.pone.0229607
doi: 10.1371/journal.pone.0229607
pubmed: 32106239
pmcid: 7046272
Park HY, Kim KW, Yoon MA et al (2020) Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. Cancer Imaging 20:14. https://doi.org/10.1186/s40644-020-0293-6
doi: 10.1186/s40644-020-0293-6
pubmed: 32000858
pmcid: 6993415
Whiting PF, Rutjes AWS, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536. https://doi.org/10.7326/0003-4819-155-8-201110180-00009
doi: 10.7326/0003-4819-155-8-201110180-00009
pubmed: 22007046
Sheldon J, Wheeler RD, Powles R (2017) Electrophoretic patterns post daratumumab. Ann Clin Biochem 55:299–301. https://doi.org/10.1177/0004563217710489
doi: 10.1177/0004563217710489
pubmed: 28490184
Udd KA, Spektor TM, Berenson JR (2017) Monitoring multiple myeloma. Clin Adv Hematol Oncol 15:951–961
pubmed: 29315287
Caers J, Laurent G, Martin Kortüm K et al (2018) European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica 103:1772–1784. https://doi.org/10.3324/haematol.2018.189159
doi: 10.3324/haematol.2018.189159
pubmed: 30171031
pmcid: 6278986
Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327:557–560
doi: 10.1136/bmj.327.7414.557
Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629–634. https://doi.org/10.1136/bmj.315.7109.629
doi: 10.1136/bmj.315.7109.629
Peters JL, Sutton AJ, Jones DR et al (2008) Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61:991–996. https://doi.org/10.1016/j.jclinepi.2007.11.010
doi: 10.1016/j.jclinepi.2007.11.010
pubmed: 18538991
R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/
Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81–92. https://doi.org/10.1016/j.eururo.2016.05.033
doi: 10.1016/j.eururo.2016.05.033
pubmed: 27317091
pmcid: 5176005
Messiou C, Collins DJ, Morgan VA, Desouza NM (2011) Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 21:1713–1718. https://doi.org/10.1007/s00330-011-2116-4
doi: 10.1007/s00330-011-2116-4
pubmed: 21472473
Koh D-M, Blackledge M, Collins DJ et al (2009) Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 19:2728–2738. https://doi.org/10.1007/s00330-009-1469-4
doi: 10.1007/s00330-009-1469-4
pubmed: 19547986
Kloth JK, Hillengass J, Listl K et al (2014) Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity. Int J Cancer 135:2380–2386. https://doi.org/10.1002/ijc.28877
doi: 10.1002/ijc.28877
pubmed: 24706394
Koutoulidis V, Fontara S, Terpos E et al (2017) Quantitative diffusion-weighted imaging of the bone marrow: an adjunct tool for the diagnosis of a diffuse MR imaging pattern in patients with multiple myeloma. Radiology 282:484–493. https://doi.org/10.1148/radiol.2016160363
doi: 10.1148/radiol.2016160363
pubmed: 27610934
Anderson KC (2017) Should minimal residual disease negativity be the end point of myeloma therapy? Blood Adv 1:517–521. https://doi.org/10.1182/bloodadvances.2016000117
doi: 10.1182/bloodadvances.2016000117
pubmed: 29296970
pmcid: 5728451
Rasche L, Alapat D, Kumar M et al (2019) Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia 33:1713–1722. https://doi.org/10.1038/s41375-018-0329-0
doi: 10.1038/s41375-018-0329-0
pubmed: 30573775
Zamagni E, Tacchetti P, Barbato S, Cavo M (2020) Role of imaging in the evaluation of minimal residual disease in multiple myeloma patients. J Clin Med 9:3519. https://doi.org/10.3390/jcm9113519
doi: 10.3390/jcm9113519
pmcid: 7692446
Lokhorst HM, Plesner T, Laubach JP et al (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373:1207–1219. https://doi.org/10.1056/NEJMoa1506348
doi: 10.1056/NEJMoa1506348
pubmed: 26308596
Raje N, Berdeja J, Lin Y et al (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380:1726–1737. https://doi.org/10.1056/NEJMoa1817226
doi: 10.1056/NEJMoa1817226
pubmed: 31042825
pmcid: 8202968
Yan Z, Cao J, Cheng H et al (2019) A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 6:e521–e529. https://doi.org/10.1016/S2352-3026(19)30115-2
doi: 10.1016/S2352-3026(19)30115-2
pubmed: 31378662
Mikkilineni L, Kochenderfer JN (2021) CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 18:71–84. https://doi.org/10.1038/s41571-020-0427-6
doi: 10.1038/s41571-020-0427-6
pubmed: 32978608